Molecular Targeting Technologies, Inc. (MTTI) is a privately held biotechnology company founded to develop small molecules for the molecular imaging of diseases such as cancer, bacterial infections, neurodegenerative diseases, cardiovascular ischemia and stroke. MTTI is also advancing a therapeutic human monoclonal antibody for Rabies post-exposure treatment and Fusion Protein Technology for development of a Botulinum neurotoxin vaccine. MTTI also develops novel medical imaging products such as PSVue® for the diagnostic and molecular imaging of cancer and bacterial infections. A leading indication for PSVue® is the imaging of tumor cell death in response to chemotherapy. Early assessment of therapy at the molecular level would allow a change of treatment when therapy is ineffective, thereby limiting unnecessary treatment and associated costs. In addition, MTTI develops fluorescent probes and other research tools for use by the research community. Current product lines include CellVue®, NeuroVue®, PSVue®, SRfluor®, and immobilized affinity steroid beads.
